{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:51:39Z","timestamp":1780455099011,"version":"3.54.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1097\/cji.0b013e3181891574","type":"journal-article","created":{"date-parts":[[2008,10,16]],"date-time":"2008-10-16T07:08:36Z","timestamp":1224140916000},"page":"849-857","source":"Crossref","is-referenced-by-count":48,"title":["Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF"],"prefix":"10.1097","volume":"31","author":[{"given":"Padmanee","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean F.","family":"Bajorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim A.","family":"Jungbluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd J.","family":"Old","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210227","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1200\/JCO.2006.08.5431","article-title":"Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments","volume":"24","author":"Parekh","year":"2006","journal-title":"J Clin Oncol"},{"key":"R2-7-20210227","first-page":"1","article-title":"Treatment of locally advanced bladder cancer","volume":"6","author":"Sharma","year":"2001","journal-title":"Princ Pract Oncol Updates"},{"key":"R3-7-20210227","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-5347(17)37452-9","article-title":"Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup","volume":"147","author":"Herr","year":"1992","journal-title":"J Urol"},{"key":"R4-7-20210227","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-5347(17)34865-6","article-title":"Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder","volume":"151","author":"Amling","year":"1994","journal-title":"J Urol"},{"key":"R5-7-20210227","first-page":"18","article-title":"Overview of treatment of superficial bladder cancer","volume":"26","author":"Soloway","year":"1985","journal-title":"Urology"},{"key":"R6-7-20210227","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2326::AID-CNCR17>3.0.CO;2-T","article-title":"Predicting the survival of bladder carcinoma patients treated with radical cystectomy","volume":"88","author":"Cheng","year":"2000","journal-title":"Cancer"},{"key":"R7-7-20210227","first-page":"53","article-title":"Review of metastatic bladder cancer","volume":"58","author":"Pagliaro","year":"2006","journal-title":"Minerva Urol Nefrol"},{"key":"R8-7-20210227","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1073\/pnas.0611618104","article-title":"CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma","volume":"104","author":"Sharma","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"R9-7-20210227","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2051-1426-3-S2-O19","article-title":"Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer","volume":"3","author":"Sharma","year":"2003","journal-title":"Cancer Immun"},{"key":"R10-7-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","article-title":"NY-ESO-1: review of an immunogenic tumor antigen","volume":"95","author":"Gnjatic","year":"2006","journal-title":"Adv Cancer Res"},{"key":"R11-7-20210227","first-page":"1","article-title":"The cancer\/testis genes: review, standardization, and commentary","volume":"4","author":"Scanlan","year":"2004","journal-title":"Cancer Immun"},{"key":"R12-7-20210227","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ijc.1282","article-title":"Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues","volume":"92","author":"Jungbluth","year":"2001","journal-title":"Int J Cancer"},{"key":"R13-7-20210227","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1158\/1078-0432.CCR-06-0527","article-title":"Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma","volume":"12","author":"Sharma","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R14-7-20210227","doi-asserted-by":"crossref","first-page":"10917","DOI":"10.1073\/pnas.97.20.10917","article-title":"Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele","volume":"97","author":"Gnjatic","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"R15-7-20210227","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.187.8.1349","article-title":"A survey of the humoral immune response of cancer patients to a panel of human tumor antigens","volume":"187","author":"Stockert","year":"1998","journal-title":"J Exp Med"},{"key":"R16-7-20210227","doi-asserted-by":"crossref","first-page":"8862","DOI":"10.1073\/pnas.1133324100","article-title":"Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses","volume":"100","author":"Gnjatic","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"R17-7-20210227","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-1759(03)00209-6","article-title":"Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC","volume":"278","author":"Atanackovic","year":"2003","journal-title":"J Immunol Methods"},{"key":"R18-7-20210227","doi-asserted-by":"crossref","first-page":"12198","DOI":"10.1073\/pnas.220413497","article-title":"Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers","volume":"97","author":"Jager","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"R19-7-20210227","doi-asserted-by":"crossref","first-page":"11813","DOI":"10.1073\/pnas.142417699","article-title":"CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients","volume":"99","author":"Gnjatic","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"R20-7-20210227","first-page":"9734","article-title":"Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans","volume":"102","author":"Davis","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R21-7-20210227","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1073\/pnas.0703395104","article-title":"Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody\/Th1 responses and CD8T cells through cross-priming","volume":"104","author":"Valmori","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"R22-7-20210227","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1073\/pnas.0707140104","article-title":"Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming","volume":"105","author":"Atanackovic","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"R23-7-20210227","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"R24-7-20210227","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.0105-2896.2006.00391.x","article-title":"CD8+ T-cell memory in tumor immunology and immunotherapy","volume":"211","author":"Klebanoff","year":"2006","journal-title":"Immunol Rev"},{"key":"R25-7-20210227","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.0105-2896.2006.00381.x","article-title":"CD4+ memory T cells: functional differentiation and homeostasis","volume":"211","author":"Stockinger","year":"2006","journal-title":"Immunol Rev"},{"key":"R26-7-20210227","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4049\/jimmunol.181.1.776","article-title":"Immunotherapy for malignant melanoma using recombinant NY-ESO-1 protein and Toll-like receptor 7 agonist imiquimod as vaccine adjuvant","volume":"181","author":"Adams","year":"2008","journal-title":"J Immunol"},{"key":"R27-7-20210227","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00002371-200405000-00002","article-title":"Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression","volume":"27","author":"Khong","year":"2004","journal-title":"J Immunother"},{"key":"R28-7-20210227","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.4049\/jimmunol.175.9.6169","article-title":"Tumor progression can occur despite the induction of very high levels of self\/tumor antigen-specific CD8T cells in patients with melanoma","volume":"175","author":"Rosenberg","year":"2005","journal-title":"J Immunol"},{"key":"R29-7-20210227","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-07-4619","article-title":"Safety and immunogenicity study of NY-ESO1b peptide and Montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission","volume":"14","author":"Diefenbach","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R30-7-20210227","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","article-title":"Checkpoint blockade in cancer immunotherapy","volume":"90","author":"Korman","year":"2006","journal-title":"Adv Immunol"},{"key":"R31-7-20210227","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.seminoncol.2006.12.004","article-title":"Immunotherapeutic strategies for high-risk bladder cancer","volume":"34","author":"Sharma","year":"2007","journal-title":"Semin Oncol"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CJI.0b013e3181891574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T20:02:55Z","timestamp":1621886575000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002371-200811000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e3181891574","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}